The Salivary Raman COVID-19 Fingerprint

NCT ID: NCT04583306

Last Updated: 2022-05-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-06-01

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The outbreak of coronavirus disease 2019 (COVID-19), caused by infection of SARS-CoV-2, has rapidly spread to become a worldwide pandemic. Global research focused on the understanding of the biochemical infective mechanism and on the discovery of a fast, sensitive and cheap diagnostic tool, able to discriminate the current and past SARS-CoV-2 infections from a minimal invasive biofluid. The fast diagnosis of COVID-19 is fundamental in order to limit and isolate the positive cases, decreasing with a prompt intervention the infection spreading.

The aim of the project is to characterize and validate the salivary Raman fingerprint of COVID-19, understanding the principal biomolecules involved in the differences between the three experimental groups: 1) healthy subjects, 2) COVID-19 patients and 3) subjects with a past infection by COVID-19. The large amount of Raman data will be used to create a salivary Raman database, associating each data with the relative clinical data collected.

Starting from the preliminary results and protocols of the Laboratory of Nanomedicine and Clinical Biophotonics (LABION) - IRCCS Fondazione Don Gnocchi Milano, the saliva collected from each experimental group will be analysed using Raman spectroscopy. All the data will be processed for the baseline, shift and normalization in order to homogenize the signals collected and creating in this way the Raman database. The average spectrum calculated from each group will be characterized, identifying the principal families of biological molecules responsible for the spectral differences.

EXPECTED RESULTS: Verify the possibility to use Raman spectroscopy on saliva samples for the identification of subjects affected by COVID-19. The principal aim of the project is to create a classification model able to: discriminate COVID-19 current and past infection, identify the principal biological molecules altered in saliva during the infection, predict the clinical course of newly diagnosed COVID-19 patients, translation and application of the classification model to a portable Raman for the test of a point of care.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

BACKGROUND/RATIONALE: The outbreak of coronavirus disease 2019 (COVID-19), caused by infection of SARS-CoV-2, has rapidly spread to become a worldwide pandemic. Global research focused on the understanding of the biochemical infective mechanism and on the discovery of a fast, sensitive and cheap diagnostic tool, able to discriminate the current and past SARS-CoV-2 infections from a minimal invasive biofluid. The fast diagnosis of COVID-19 is fundamental in order to limit and isolate the positive cases, decreasing with a prompt intervention the infection spreading. Moreover, the prediction of the respiratory infection severity could be of crucial importance for the fast identification and discrimination between mild clinical course, severe illness, and Acute Respiratory Distress Syndrome (ARDS). One of the first infection sites of SARS-CoV-2 is the oral cavity where the virus is able to bind and penetrate through the ACE2 receptors present on the epithelial cells of the salivary glands. Thus, a high concentration of virus particles could be found in saliva in the preliminary phases of the infection. Saliva is a complex biofluid composed of bioactive molecules that can be collected with a really minimal-invasive procedure. Raman spectroscopy is a non-invasive, fast and label-free vibrational technique, able to provide information regarding presence, concentration, environment, modifications and interactions of all the biochemical species present in a specific biofluid. Using the Raman spectroscopy, the investiators will analyze saliva collected from healthy subjects, patients affected by COVID-19 and subjects with a past infection by COVID-19. The data collected will be analyzed and used to create a Raman database able to provide a classification model based on machine learning. The possibility to monitor and characterize a potential salivary COVID-19 fingerprint could be of crucial importance for the monitoring and discrimination of COVID-19 subjects with a current and past infection from the healthy subjects.

OBJECTIVES: The aim of the project is to characterize and validate the salivary Raman fingerprint of COVID-19, understanding the principal biomolecules involved in the differences between the three experimental groups: 1) healthy subjects, 2) COVID-19 patients and 3) subjects with a past infection by COVID-19. The large amount of Raman data will be used to create a salivary Raman database, associating each data with the relative clinical data collected. The Raman database will be used for the creation of a classification model through the application of multivariate analysis in terms of principal component analysis and linear discriminant analysis. This classification model will provide a fast tool for the discrimination of the COVID-19 condition, potentially providing also information on the respiratory clinical course of the patient. The model will be translated for the application to a portable Raman spectrometer, leading to the creation of a Raman Point of Care METHODS: Starting from the preliminary results and protocols of the Laboratory of Nanomedicine and Clinical Biophotonics (LABION) - IRCCS Fondazione Don Gnocchi Milano, the saliva collected from each experimental group will be analysed using Raman spectroscopy. All the data will be processed for the baseline, shift and normalization in order to homogenize the signals collected and creating in this way the Raman database. The average spectrum calculated from each group will be characterized, identifying the principal families of biological molecules responsible for the spectral differences. Consecutively, all the spectra will be processed through multivariate analysis (principal component analysis and linear discriminant analysis) obtaining in this way the classification model. LOOCV will be used for the training of the classification model, which will be questioned using the subset validation analysis. The partial correlation coefficient (Pearson's and Spearman's correlation) will be used for the Raman correlation with the clinical parameter (e.g. COVID-19 clinical course) using as control covariates the age and sex of the subjects. The classification model will be then translated and used as point of care using a portable Raman equipped with a laser emitting at 785 nm, with a comparable spectral resolution.

* SAMPLE COLLECTION: Saliva will be collected with Salivette (SARSTEDT, Germany), following the manufacturer's instructions. The cotton swab will be inserted in the subject mouth and chewed for 60 seconds. The saliva collection will be achieved through centrifugation of the swab (1000 g x 2 min), recording all the related parameters (storage temperature and the time between collection and analysis). All the collection procedures will be performed at least two hours after the last meal and teeth brushing.
* SAMPLE PROCESSING: Before the analysis, saliva (3 ul) will be deposited on aluminum foil and dried overnight. The aluminum foil is fundamental to achieve the Surface Enhanced Raman Scattering, increasing the saliva Raman signal.
* DATA COLLECTION: Raman spectra will be acquired using an Aramis Raman microscope (Horiba Jobin-Yvon, France) equipped with a laser light source operating at 785 nm with 100% (512mW) laser power. Acquisition time will be set at 30 seconds with double acquisition and 2 seconds delay time to prevent the formation of artifact spectra. Before each analysis, the instrument will be calibrated using the reference band of silicon. All the signals will be acquired in the region between 400 and 1600 cm-1 with a resolution of 0.8cm-1, acquiring at least 25 spectra following a square-map. The software package LabSpec 6 (Horiba Jobin-Yvon) will be used for map design and the acquisition of spectra.
* DATA ANALYSIS: All the data will be fit using a fourth-degree polynomial curve to set the baseline and consecutively normalized using unit vector. The contribution of aluminum will be removed from each spectrum. The statistical analysis will be performed using the multivariate approach. Briefly, principal component analysis and linear discriminant analysis will be applied to extract the principal components and the canonical variables. These features will be used for the leave one out cross-validation (LOOCV), subset validation and correlation with the clinical parameters. Mann-Whitney will be performed on PCs scores to verify the differences statistically relevant between the analysed groups. The analysis will be performed using Origin software (OriginLab, USA)
* CORRELATION: Partial correlation with Pearson's and Spearman's coefficients will be performed on the variables extracted and the clinical parameters, using as control covariates the age and sex of the subjects. Only values with p \< 0.001 will be considered as statistically relevant.
* TRANSLATION: The data and the classification model will be applied with a portable Raman equipped with a laser emitting at 785 nm and with a spectral resolution comparable with the one used for the previous analysis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy Subjects

40 Healthy Subjects in a good state of health comparable by age and sex with the other selected groups and with a negative test for SARS-CoV-2 or collected before the pandemic event

Raman analysis of saliva, characterization of the Raman database and building of the classification model

Intervention Type OTHER

Saliva will be collected, processed and analysed through Raman spectroscopy. Data acquired will be normalized and treated for the creation of the classification model.

COVID-19 Positive

40 subjects affected by COVID-19, determined by positive nasopharyngeal test for SARS-CoV-2 and with comparable age and sex for the other selected groups

Raman analysis of saliva, characterization of the Raman database and building of the classification model

Intervention Type OTHER

Saliva will be collected, processed and analysed through Raman spectroscopy. Data acquired will be normalized and treated for the creation of the classification model.

COVID-19 Negative

40 subjects with a past infection by SARS-CoV-2 confirmed and with at least two consecutive negative tests determined by nasopharyngeal SARS-CoV-2 assay, comparable by age and sex with the other selected groups

Raman analysis of saliva, characterization of the Raman database and building of the classification model

Intervention Type OTHER

Saliva will be collected, processed and analysed through Raman spectroscopy. Data acquired will be normalized and treated for the creation of the classification model.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Raman analysis of saliva, characterization of the Raman database and building of the classification model

Saliva will be collected, processed and analysed through Raman spectroscopy. Data acquired will be normalized and treated for the creation of the classification model.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of COVID-19 through nasopharyngeal swab positive for SARS-CoV-2
* Provided written consent for the salivary analysis
* Age between 18 and 90 years

Exclusion Criteria

* Oral bacterial or fungal infection in progress (e.g. oral candidiasis)
* Age lower than 18 and higher than 90 years
* No written consent provided
Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Fondazione Don Carlo Gnocchi Onlus

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Marzia Bedoni, PhD

Role: STUDY_CHAIR

IRCCS Fondazione Don Carlo Gnocchi, Laboratory of Nanomedicine and Clinical Biophotonics

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Azienda Ospedaliera Universitaria Policlinico di Bari

Bari, Apulia, Italy

Site Status RECRUITING

Fondazione Don Carlo Gnocchi, Centro Spalenza

Rovato, BS, Italy

Site Status RECRUITING

IRCCS Fondazione Don Carlo Gnocchi, Santa Maria Nascente Hospital (Milano)

Milan, MI, Italy

Site Status RECRUITING

Farmaacquisition srl

Milan, , Italy

Site Status RECRUITING

Università degli Studi di Milano-Bicocca

Milan, , Italy

Site Status ACTIVE_NOT_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Italy

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Marzia Bedoni, PhD

Role: CONTACT

0240308874 ext. +39

LABION laboratory

Role: CONTACT

0240308533 ext. +39

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Paola Pierucci, MD

Role: primary

Luca C Bianchi, MD

Role: primary

03072245414 ext. +39

Marzia Bedoni, PhD

Role: primary

0240308874 ext. +39

LABION laboratory

Role: backup

0240308533 ext. +39

Maria Langerame

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Feng Z, Yu Q, Yao S, Luo L, Zhou W, Mao X, Li J, Duan J, Yan Z, Yang M, Tan H, Ma M, Li T, Yi D, Mi Z, Zhao H, Jiang Y, He Z, Li H, Nie W, Liu Y, Zhao J, Luo M, Liu X, Rong P, Wang W. Early prediction of disease progression in COVID-19 pneumonia patients with chest CT and clinical characteristics. Nat Commun. 2020 Oct 2;11(1):4968. doi: 10.1038/s41467-020-18786-x.

Reference Type BACKGROUND
PMID: 33009413 (View on PubMed)

Carlomagno C, Cabinio M, Picciolini S, Gualerzi A, Baglio F, Bedoni M. SERS-based biosensor for Alzheimer disease evaluation through the fast analysis of human serum. J Biophotonics. 2020 Mar;13(3):e201960033. doi: 10.1002/jbio.201960033. Epub 2020 Jan 1.

Reference Type BACKGROUND
PMID: 31868266 (View on PubMed)

Carlomagno C, Banfi PI, Gualerzi A, Picciolini S, Volpato E, Meloni M, Lax A, Colombo E, Ticozzi N, Verde F, Silani V, Bedoni M. Human salivary Raman fingerprint as biomarker for the diagnosis of Amyotrophic Lateral Sclerosis. Sci Rep. 2020 Jun 23;10(1):10175. doi: 10.1038/s41598-020-67138-8.

Reference Type BACKGROUND
PMID: 32576912 (View on PubMed)

Gualerzi A, Niada S, Giannasi C, Picciolini S, Morasso C, Vanna R, Rossella V, Masserini M, Bedoni M, Ciceri F, Bernardo ME, Brini AT, Gramatica F. Raman spectroscopy uncovers biochemical tissue-related features of extracellular vesicles from mesenchymal stromal cells. Sci Rep. 2017 Aug 29;7(1):9820. doi: 10.1038/s41598-017-10448-1.

Reference Type BACKGROUND
PMID: 28852131 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://www.labion.eu/

Laboratory of Nanomedicine and Clinical Biophotonics at IRCCS Fondazione Don Carlo Gnocchi ONLUS, Milano (Italy)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FDG_SalivaCOVID01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Salivary Biomarkers for Concussion
NCT06149351 RECRUITING NA